Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature

Published:2022-12 Issue: Volume:8 Page:100190
ISSN:2666-6219
Container-title:Current Problems in Cancer: Case Reports
language:en
Short-container-title:Current Problems in Cancer: Case Reports

Author:

Chaudhry Akriti,Schuppe Kyle,Burke Skyler,Lobova Veronika,Seigel Quincy,Kirby Carsten,Chitlik Sara,Andrei Mirela,Kaya Erin^ORCID

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. Emerging resistance pathways in lung cancer: what has ROS-1 taught us?;Alrifai;Transl. Lung Cancer Res.,2018

2. Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers;Choudhury;JTO Clin. Res. Rep.,2021

3. Cell death-based treatment of lung adenocarcinoma;Denisenko;Cell Death Dis.,2018

4. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N. Engl. J. Med.,2018

5. Pembrolizumab for the treatment of non–small-cell lung cancer;Garon;N. Engl. J. Med.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP